Robert M. Goldberg, PhD
Vice President and Co-Founder
Center for Medicine in the Public Interest
Robert Goldberg is Vice President and co-founder of the Center for Medicine in the Public Interest (www.cmpi.org), a non-profit organization that advocates for consumer access to medical innovation.
Prior to founding CMPI, Goldberg was Director of the Manhattan Institute's Center for Medical Progress and Chairman of its 21st Century FDA Task Force that recommended ways to reduce the time and cost of getting innovative medicines to patients. Many of these recommendations are included in the 21st Century Cures Act.
Dr. Goldberg’s current research focuses on comparing the impact of PBM formulary decisions and value frameworks to personalized medicine on health outcomes. On a related matter, he has advised HHS, the VA and FDA on the limits of traditional approaches to data analysis currently used by PBMs, insurers and policymakers on generating reliable real-world evidence of clinical benefit.
He is an adviser to Nonpareil, a biotech commercialization accelerator and consults for several biopharmaceutical companies on reimbursement, market access and patient-centered value. He is the co-founder of Transforming Medicine: The Elizabeth Kauffman Institute, a non profit personalized medicine accelerator.
Dr. Goldberg is also the author of “Tabloid Medicine: How the Internet is Being Used to Hijack Medical Science for Fear and Profit.” (Kaplan, 2011). In addition to publishing in peer-reviewed journals such as Pharmacoeconomics and JAMA, has written for Scientific American, The New York Post, Morning Consult, and The Washington Post. Along with CMPI co-founded Peter Pitts, he writes for Drugwonks.com, one of the mostly widely read blogs on medical innovation and drug regulation.
Dr. Goldberg received his PhD in Politics from Brandeis University in 1984 and is a devoted Yankee fan and father of two children, Sara 33 and Zach, 30.